Nipro Diagnostics, Inc., and NeuroMetrix, Inc., have announced that they will seek opportunities to sell their soon-to-be-introduced NC-stat® DPNCheckTM neuropathy test in retail medical clinics nationwide. The test, conducted onsite, evaluates neuropathies, including diabetic peripheral neuropathy (DPN).
DPN, which affects more than half of all people with diabetes, is a condition in which the lower limbs lose sensation. Lack of ability to perceive injuries, as well as the slower healing process brought on by diabetes, can result in stubborn foot ulcers that lead to amputation.
The companies are hoping that the test will provide an accessible, cost-effective approach to detecting DPN and other neuropathic conditions. Their target market, retail medical clinics, is one of the fastest growing provider segments of the healthcare system. Nipro and NeuroMetrix estimate that there are now 1,200 such clinics operating in the United States, a figure that is growing at a double-digit annual rate.
Often located alongside chain drug store and department store pharmacies, retail medical clinics offer urgent, convenient medical care, including vaccinations, treatment of minor injuries and chronic conditions, and diagnostic procedures such as blood tests. Many clinics are beginning to provide expanded services for certain disease states such as diabetes.
Florida-based Nipro Diagnostics, a subsidiary of Japan-based Nipro Corporation, manufactures and markets blood glucose monitoring systems, including private-label lines. Massachusetts-based NeuroMextrix develops and markets products for the detection, diagnosis, and monitoring of peripheral nerve disorders.